In summary, under the Trump plan, the U.S. health system continues to fail Americans — by not viewing obesity as a disease, ...

Twenty-two years since the series' 2003 premiere, the stylist reflects on his role evolving society toward greater compassion ...

Apple became the first $1 trillion company on U.S. public markets in 2018. Six of the eight companies to follow in Apple’s ...

Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the ...

GLP-1 weight-loss drugs like Wegovy and Zepbound from patients who lose only moderate amounts of weight at best, according to ...

Though healthcare stocks have been much more measured this year, there are bright spots there as well. The medical-device maker Medtronic (MDT) closed at its highest price since May 12, 2022, after ...

Lilly's tirzepatide is sold as Mounjaro for Type 2 diabetes and as Zepbound for weight loss -- but doctors have prescribed ...

Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...

Novo Nordisk announced Monday that it is significantly cutting the prices of its blockbuster GLP-1 drugs, Wegovy (for weight ...

Let’s delve into the details of each of the evaluated factors, but first, for a quick background: With a $917 Bil market cap, ...

Eli Lilly and Company (NYSE: LLY) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 7, TD Cowen ...

Medicare to cover obesity drugs under Trump deal for as little as $50. Kathryn Pomroy, Kiplinger’s Consumer News Service, Premium Health News Service Posted 11/18/2025 at 08:05 ...